Laura Archer

2.8k total citations · 1 hit paper
27 papers, 1.5k citations indexed

About

Laura Archer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Nephrology. According to data from OpenAlex, Laura Archer has authored 27 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Nephrology. Recurrent topics in Laura Archer's work include Prostate Cancer Treatment and Research (4 papers), Prostate Cancer Diagnosis and Treatment (3 papers) and Medication Adherence and Compliance (3 papers). Laura Archer is often cited by papers focused on Prostate Cancer Treatment and Research (4 papers), Prostate Cancer Diagnosis and Treatment (3 papers) and Medication Adherence and Compliance (3 papers). Laura Archer collaborates with scholars based in United States, Canada and United Kingdom. Laura Archer's co-authors include Susan Halabi, Eric J. Small, Jonathan E. Rosenberg, Daniel A. Vaena, Walter M. Stadler, James N. Atkins, Janice P. Dutcher, San-San Ou, Joel Picus and Brian I. Rini and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Laura Archer

27 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

2008 707 citations Brian I. Rini, Susan Halabi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura Archer United States	17	859	532	527	482	168	27	1.5k
Serge Benayoun Canada	12	1.4k 1.6×	191 0.4×	384 0.7×	242 0.5×	379 2.3×	24	2.0k
Piotr Czaykowski Canada	23	1.2k 1.4×	796 1.5×	857 1.6×	604 1.3×	440 2.6×	89	2.2k
Monique M.E.M. Bos Netherlands	19	667 0.8×	527 1.0×	1.1k 2.1×	407 0.8×	203 1.2×	36	2.1k
Bethany B Barone United States	14	379 0.4×	1.1k 2.0×	756 1.4×	370 0.8×	276 1.6×	22	1.9k
Lore Decoster Belgium	23	1.0k 1.2×	328 0.6×	1.4k 2.6×	218 0.5×	274 1.6×	102	2.8k
Matthew S. Ning United States	19	608 0.7×	121 0.2×	544 1.0×	100 0.2×	211 1.3×	89	1.4k
E. Maartense Netherlands	17	427 0.5×	150 0.3×	1.3k 2.4×	346 0.7×	74 0.4×	49	2.0k
V. Girre France	16	368 0.4×	137 0.3×	630 1.2×	171 0.4×	101 0.6×	29	1.3k
Shital Kamble United States	16	380 0.4×	213 0.4×	1.4k 2.6×	297 0.6×	323 1.9×	36	2.4k
J. J. Nicoll United Kingdom	14	315 0.4×	89 0.2×	394 0.7×	258 0.5×	142 0.8×	33	1.1k

Countries citing papers authored by Laura Archer

Since Specialization

Citations

This map shows the geographic impact of Laura Archer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Archer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Archer more than expected).

Fields of papers citing papers by Laura Archer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Archer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Archer. The network helps show where Laura Archer may publish in the future.

Co-authorship network of co-authors of Laura Archer

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Archer. A scholar is included among the top collaborators of Laura Archer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Archer. Laura Archer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Archer, Laura, et al.. (2018). International Emergency Medical Teams Training Workshop Special Report. Prehospital and Disaster Medicine. 33(3). 335–338. 10 indexed citations

Demmy, Todd L., Lin Gu, Jack E. Burkhalter, et al.. (2012). Optimal Management of Malignant Pleural Effusions (Results of CALGB 30102). Journal of the National Comprehensive Cancer Network. 10(8). 975–982. 71 indexed citations

Cohen, Harvey Jay, Lan Lan, Laura Archer, & Alice B. Kornblith. (2012). Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803). Journal of Geriatric Oncology. 3(2). 82–89. 32 indexed citations

Ruddy, Kathryn J., Laura Archer, H. J. Cohen, et al.. (2012). Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Annals of Oncology. 23(12). 3075–3081. 22 indexed citations

Katz, Mira L., Laura Archer, Jeffrey Peppercorn, et al.. (2012). Patient advocates' role in clinical trials. Cancer. 118(19). 4801–4805. 25 indexed citations

Shapiro, Charles L., Susan Halabi, Vera Hárs, et al.. (2011). Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809. European Journal of Cancer. 47(5). 683–689. 81 indexed citations

Hurwitz, Mark, Susan Halabi, Laura Archer, et al.. (2011). Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate‐risk prostate cancer. Cancer. 117(24). 5579–5588. 22 indexed citations

Romanus, Dorothy, Hedy L. Kindler, Laura Archer, et al.. (2011). Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). Journal of Pain and Symptom Management. 43(2). 205–217. 56 indexed citations

Garber, J. E., Susan Halabi, Sara M. Tolaney, et al.. (2010). Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer. JNCI Journal of the National Cancer Institute. 102(13). 942–949. 40 indexed citations

10.

Swaminathan, Madhav, Laura Archer, Jula K. Inrig, et al.. (2010). Perioperative outcomes among patients with end-stage renal disease following coronary artery bypass surgery in the USA. Nephrology Dialysis Transplantation. 25(7). 2275–2283. 31 indexed citations

11.

Demmy, Todd L., Lixu Gu, Jack E. Burkhalter, et al.. (2010). Comparison of in-dwelling catheters and talc pleurodesis in the management of malignant pleural effusions.. Journal of Clinical Oncology. 28(15_suppl). 9031–9031. 5 indexed citations

12.

Martinelli, Susan M., Uptal D. Patel, Barbara G. Phillips‐Bute, et al.. (2009). Trends in Cardiac Surgery-Associated Acute Renal Failure in the United States: A Disproportionate Increase after Heart Transplantation. Renal Failure. 31(8). 633–640. 16 indexed citations

13.

Linker, Claudia, Kouros Owzar, Bayard L. Powell, et al.. (2009). Auto-SCT for AML in second remission: CALGB Study 9620. Bone Marrow Transplantation. 44(6). 353–359. 25 indexed citations

14.

Schrag, Deborah, Michelle J. Naughton, Aaron S. Kesselheim, et al.. (2009). Clinical trial participants’ strategies for coping with prescription drug costs: A companion study to CALGB 80405. Journal of Clinical Oncology. 27(15_suppl). 9503–9503. 10 indexed citations

15.

Swaminathan, Madhav, Barbara G. Phillips‐Bute, Uptal D. Patel, et al.. (2009). Increasing Healthcare Resource Utilization After Coronary Artery Bypass Graft Surgery in the United States. Circulation Cardiovascular Quality and Outcomes. 2(4). 305–312. 28 indexed citations

16.

D’Amico, Anthony V., Susan Halabi, Robin T. Vollmer, et al.. (2008). p53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology. 71(5). 933–937. 17 indexed citations

17.

Rini, Brian I., Susan Halabi, Jonathan E. Rosenberg, et al.. (2008). Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206. Journal of Clinical Oncology. 26(33). 5422–5428. 707 indexed citations breakdown →

18.

Swaminathan, Madhav, Andrew Shaw, Barbara G. Phillips‐Bute, et al.. (2007). Trends in acute renal failure associated with coronary artery bypass graft surgery in the United States. Critical Care Medicine. 35(10). 2286–2291. 52 indexed citations

19.

Schrag, Deborah, Laura Archer, X. Wang, et al.. (2007). A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303. Journal of Clinical Oncology. 25(18_suppl). 4524–4524. 14 indexed citations

20.

D’Amico, Anthony V., Susan Halabi, R T Vollmer, et al.. (2007). p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study. International Journal of Radiation Oncology*Biology*Physics. 69(3). S333–S333. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact